Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23094
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSeymour, John F-
dc.contributor.authorMarcus, Robert-
dc.contributor.authorDavies, Andrew-
dc.contributor.authorGallop-Evans, Eve-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorHaynes, Andrew-
dc.contributor.authorHerold, Michael-
dc.contributor.authorIllmer, Thomas-
dc.contributor.authorNilsson-Ehle, Herman-
dc.contributor.authorSökler, Martin-
dc.contributor.authorDünzinger, Ulrich-
dc.contributor.authorNielsen, Tina-
dc.contributor.authorLaunonen, Aino-
dc.contributor.authorHiddemann, Wolfgang-
dc.date.accessioned2020-05-05T23:59:23Z-
dc.date.available2020-05-05T23:59:23Z-
dc.date.issued2020-05-
dc.identifier.citationHaematologica 2020; 105(5): 1465-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/23094-
dc.language.isoeng-
dc.titleAssociation of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.-
dc.typeJournal Article-
dc.identifier.journaltitleHaematologica-
dc.identifier.affiliationPeter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationKings College Hospital, London, UK-
dc.identifier.affiliationF. Hoffmann-La Roche Ltd., Basel, Switzerlanden
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCancer Research UK Centre, University of Southampton, Southampton, UK-
dc.identifier.affiliationVelindre Cancer Centre, Cardiff, UK-
dc.identifier.affiliationNottingham University Hospitals NHS Trust, Nottingham, UK-
dc.identifier.affiliationHELIOS-Klinikum Erfurt, Germany-
dc.identifier.affiliationBAG Freiberg-Richter, Jacobasch, Illmer and Wolf, Dresden, Germany-
dc.identifier.affiliationSection of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden-
dc.identifier.affiliationEberhard-Karls-University Tübingen, Tübingen, Germany-
dc.identifier.affiliationRoche Pharma AG, Grenzach-Wyhlen, Germany-
dc.identifier.affiliationDepartment of Medicine III, Ludwig-Maximilians-University, München, Germany-
dc.identifier.doi10.3324/haematol.2020.246991-
dc.identifier.pubmedid32358081-
dc.type.austinJournal Article-
dc.type.austinPublished Erratum-
local.name.researcherGrigg, Andrew P
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Dec 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.